The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumab
Pau Abrisqueta, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, outlines developments in bispecific antibodies for diffuse large B-cell lymphoma (DLBCL), highlighting trial data on glofitamab, odronextamab, epcoritamab & mosunetuzumab presented at ASH 2022, and discussing the place of bispecific antibodies in the treatment regimen of DLBCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sandoz: Honoraria; BMS: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy.
